DCM
ALXN

Delpha Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Delpha Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-852
Closed -$102K – 1464
2017
Q4 		$102K Buy
+852
New +$104K 0.11% 143

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Delpha Capital Management's ALXN Position: Q1 2018 in Review

Delpha Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q1 2018, closing a stake of 852 shares — an estimated $102K sold.

Delpha Capital Management first reported a position in ALXN in Q4 2017 and held it in 1 quarter. The position peaked at $102K in Q4 2017. 597 funds tracked by Wall St. Rank hold ALXN as of Q1 2018.

  • Delpha Capital Management reported no remaining Alexion Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Delpha Capital Management sold 852 Alexion Pharmaceuticals shares in Q1 2018, an estimated $102K.
  • Delpha Capital Management first reported a position in Alexion Pharmaceuticals in Q4 2017 and held it in 1 quarter.
  • Delpha Capital Management's Alexion Pharmaceuticals position peaked at $102K in Q4 2017.
  • 597 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2018.

Based on Delpha Capital Management's 13F filing for Q1 2018, filed 11 May 2018.